{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-23-000078","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.386380+00:00","generated_at":"2026-06-08T05:58:25.297570+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Neurocrine settles all INGREZZA patent litigations; generic entry starts March 1, 2038","bullets":["Resolved patent litigation with Zydus; Zydus can sell generic INGREZZA from Oct 1, 2038 (or earlier under certain circumstances).","Prior settlements with Sandoz, Teva, and Lupin allow generic entry from March 1, 2038, subject to earlier triggers.","All ANDA-filing companies now settled, blocking generic competition until at least 2038, a significant IP win.","Settlements require FTC/DOJ review but are standard in Hatch-Waxman litigation."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-23-000078","json":"https://secwatch.observer/filing/0000914475-23-000078.json","markdown":"https://secwatch.observer/filing/0000914475-23-000078.md","text":"https://secwatch.observer/filing/0000914475-23-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000078/0000914475-23-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000078/nbix-20231110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:58:25.297570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}